Terug
26
42
31
Dagbereik
€ 23,00
€ 23,00
52-Weeksbereik
€ 20,60
€ 37,36
Volume
7
50D / 200D Gem.
€ 25,46
/
€ 28,72
Vorige Slotkoers
€ 23,00
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (631 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 3,6 | 0,3 |
| P/B | 0,8 | 3,0 |
| ROE % | 24,5 | 3,7 |
| Net Margin % | 17,0 | 3,8 |
| Rev Growth 5Y % | 20,3 | 10,0 |
| D/E | 0,4 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2028 |
€ 11,92
€ 11,49 – € 12,36
|
1,78B | 1 |
| FY2027 |
€ 9,82
€ 9,46 – € 10,18
|
1,59B | 1 |
| FY2026 |
€ 7,85
€ 7,56 – € 8,14
|
1,42B | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-12 | € 1,56 | € 0,22 | -86,1% |
| 2025-08-08 | € 0,12 | € 0,09 | -19,5% |
| 2025-05-09 | € 0,11 | € 0,17 | +45,7% |
| 2025-02-21 | € 0,12 | € 0,16 | +32,6% |
| 2024-11-08 | € 0,06 | € 0,13 | +100,3% |
| 2024-08-16 | € 0,07 | € 0,17 | +140,5% |
| 2024-05-17 | € 0,07 | € 0,10 | +39,1% |
| 2024-02-23 | € 0,07 | € 0,09 | +26,3% |
Dividend History
Yield
0,01%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| May 11, 2026 | May 15, 2026 | € 0,43 | 1,86% |
| May 23, 2025 | May 30, 2025 | € 0,31 | 0,98% |
| May 23, 2024 | May 29, 2024 | € 0,19 | 1,40% |
| May 18, 2016 | May 24, 2016 | € 0,03 | 0,21% |
| May 26, 2011 | Jun 03, 2011 | € 0,08 | 3,60% |
| May 26, 2010 | Jun 02, 2010 | € 0,06 | 2,86% |
| May 23, 2008 | May 30, 2008 | € 0,08 | 1,28% |
Belangrijkste Punten
Revenue grew 20,31% annually over 5 years — strong growth
ROE of 24,47% indicates high profitability
Net margin of 16,95% shows strong profitability
Debt/Equity of 0,40 — conservative balance sheet
Generating 158,90M in free cash flow
P/E of 3,61 — trading at a low valuation
Groei
Revenue Growth (5Y)
20,31%
Revenue (1Y)12,77%
Earnings (1Y)11,93%
FCF Growth (3Y)-19,73%
Kwaliteit
Return on Equity
24,47%
ROIC15,88%
Net Margin16,95%
Op. Margin21,74%
Veiligheid
Debt / Equity
0,40
Current Ratio1,70
Interest Coverage0,00
Waardering
P/E Ratio
3,61
Forward P/EN/A
P/B Ratio0,83
EV/EBITDA2,77
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 12,77% | Revenue Growth (3Y) | 14,68% |
| Earnings Growth (1Y) | 11,93% | Earnings Growth (3Y) | 67,11% |
| Revenue Growth (5Y) | 20,31% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,34B | Net Income (TTM) | 227,80M |
| ROE | 24,47% | ROA | 11,44% |
| Gross Margin | 92,42% | Operating Margin | 21,74% |
| Net Margin | 16,95% | Free Cash Flow (TTM) | 158,90M |
| ROIC | 15,88% | FCF Growth (3Y) | -19,73% |
| Safety | |||
| Debt / Equity | 0,40 | Current Ratio | 1,70 |
| Interest Coverage | 0,00 | ||
| Dividends | |||
| Dividend Yield | 0,01% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 3,61 | Forward P/E | N/A |
| P/B Ratio | 0,83 | P/S Ratio | 0,61 |
| PEG Ratio | 2,76 | Forward PEG | N/A |
| EV/EBITDA | 2,77 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 19,33% | ||
| Market Cap | 822,17M | Enterprise Value | 809,67M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,34B | 1,19B | 1,02B | 843,65M | 641,67M |
| Net Income | 227,80M | 203,51M | 81,57M | 23,78M | -47,32M |
| EPS (Diluted) | 6,65 | 5,94 | 2,38 | 0,69 | -1,38 |
| Gross Profit | 1,24B | 1,09B | 915,58M | 748,66M | 591,28M |
| Operating Income | 292,30M | 260,49M | 114,88M | 42,74M | -52,64M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,99B | 2,09B | 1,95B | 1,88B | 1,74B |
| Total Liabilities | 1,01B | 1,21B | 1,22B | 1,22B | 1,12B |
| Shareholders' Equity | 985,30M | 876,71M | 735,23M | 657,16M | 628,31M |
| Total Debt | 394,80M | 471,93M | 529,36M | 555,39M | 561,40M |
| Cash & Equivalents | 407,30M | 462,74M | 343,68M | 160,27M | 102,54M |
| Current Assets | 970,70M | 984,75M | 802,45M | 627,92M | 516,37M |
| Current Liabilities | 569,90M | 703,82M | 675,05M | 614,10M | 490,08M |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
#679 of 825
#239 of 618
#139 of 203
Recente Activiteit
Uitgestapt
Contrarian Investing (David Dreman)
Mar 26, 2026
Uitgestapt
Defensive Investing (Benjamin Graham)
Mar 26, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026